New hope for tough breast cancer: Two-Drug combo tested
NCT ID NCT07520760
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of two drugs, eribulin and anlotinib, for people with HER2-negative breast cancer that has spread or come back. Participants have already tried other treatments without success. The goal is to see if this combo can slow cancer growth and improve survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- eribulin and anlotinib
- What this could lead to
- If successful, this combination could offer a new treatment option for patients with HER2-negative advanced breast cancer who have run out of standard therapies.
- What could go wrong
- This is a small, early-phase study with only 52 participants, so results may not apply broadly. The combination may cause side effects or fail to improve outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER 2 NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun yat-Sen University Cancer Center
RECRUITINGGuangzhou, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.